DAY BY DAY Maintains Eurofins Scientific SE (ERFSF) Hold Recommendation

DAY BY DAY kept a Hold on Eurofins Scientific (OTCPK: ERFSF) on Dec. 9, 2025, with the analyst consensus one‑year target at $75.52 (range $55.70–$109.77), implying roughly 27.4% upside from the Dec. 6 close of $59.27. Street forecasts peg annual revenue at about $7,413m (+3.8%) and non‑GAAP EPS of 4.07, but institutional activity is mixed: 251 funds report positions (up slightly), total institutional shares slipped 1.35% to ~26.11m, and several large holders such as Oakmark and Europacific materially trimmed stakes while Sequoia and Vanguard remain significant holders. In sum, analysts see material valuation upside but the Hold rating and recent fund-level trimming point to caution as investors weigh growth prospects against portfolio reallocation risk.

Analysis

On December 9, 2025 DAY BY DAY maintained a Hold on Eurofins Scientific SE (OTCPK: ERFSF). As of December 6, 2025 the average one‑year price target is $75.52 (range $55.70–$109.77), implying 27.41% upside from the latest closing price of $59.27. Street forecasts project annual revenue of 7,413MM (+3.76%) and non‑GAAP EPS of 4.07.

Institutional positioning is mixed: 251 funds report positions (up 3 owners or 1.21% quarter over quarter) and average portfolio weight rose to 0.31% (+4.29%). Total institutional shares declined 1.35% to 26,110K, with notable rebalancing—Oakmark trimmed to 3,782K (2.14%) from 4,919K (-30.06%), Europacific cut to 1,815K from 3,317K and reduced its allocation materially, while Sequoia (2,926K) and Vanguard (1,638K) remain sizable holders.

The juxtaposition of an analyst‑implied ~27% upside with a Hold rating and recent fund‑level trimming signals that upside is valuation‑driven rather than conviction‑driven, leaving the stock vulnerable if Eurofins misses the modest growth/earnings projections. Primary near‑term risks are execution against the 3.76% revenue growth forecast, further institutional selling, and absent positive catalysts; monitor quarterly results and subsequent institutional filings as the main triggers for reassessment.

Key Decisions for Investors

• Given the 27.4% implied upside but Hold rating and recent fund trimming, avoid initiating large new positions and consider phased entries tied to confirmed quarterly revenue/EPS beats or strengthening guidance
• Existing holders should consider partial profit‑taking or hedging to protect against downside from further institutional reallocation, with explicit sell or hedge triggers tied to missed revenue or EPS targets
• Monitor next quarter's results and 13F/ownership updates closely—meaningful increases in institutional share counts or upward revisions to analyst forecasts would justify revisiting a more constructive position